Skip to main navigation
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Search
Close
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Press Release
Jul 28, 2021
| Rachel Schwartz
Joanne Duncan Joins AAM as Chief Operating Officer
Blog
Jul 19, 2021
| Craig Burton
Seniors Are Still Missing Out on Savings in Medicare Part D
Press Release
Jul 19, 2021
| Rachel Schwartz
AAM Releases New Report: New Generics Are Less Available in Medicare Than Commercial Plans
Report
Jul 13, 2021
| Erica Klinger
New Evidence Shows Medicare Part D Plans Continue to Fail to Get New Generics to Seniors
Blog
Jul 7, 2021
| Dan Leonard
Introducing the AAM All Access Podcast
Blog
Jul 6, 2021
| Erica Klinger
A New Resource Showcases Patient Stories. Are You Up Next?
Blog
Jul 1, 2021
| Bob Billings
Thank you, Eli Hurvitz
Press Release
Jul 1, 2021
| Rachel Schwartz
AAM Statement on the Anniversary of USMCA
Press Release
Jun 30, 2021
| Rachel Schwartz
AAM Statement on Gov. Mills’ Veto of LD 1117
Blog
Jun 21, 2021
| Jewel Smith
Member Spotlight: Aurobindo Pharma
Press Release
Jun 18, 2021
| Rachel Schwartz
AAM Statement on Governor Mill’s Consideration of LD 1117
Press Release
Jun 17, 2021
| Rachel Schwartz
AAM and Biosimilars Council Statement on ACA Ruling in California v. Texas
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action